Follow SELLAS Life Sciences to never miss an important update.
The Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary goal, showing that the vaccine helped patients with acute myeloid leukemia (AML) live longer. Patients receiving GPS had a median survival of 24 months compared to about 15 months for those on standard treatments. This represents a 41 percent reduction in the risk of death.
This is the most critical milestone in the company's history. As a clinical-stage biotech with no products on the market, the entire business was essentially a bet on this specific trial. These results provide the data needed to seek regulatory approval, which would transform the company from a research firm into a commercial drug maker.
Source: GlobeNewsWire
The company reported a quarterly loss of 5 cents per share, which matched what analysts expected. More importantly for a biotech firm with no revenue, it ended September with about 135 million dollars in cash. This is a significant increase from the 72 million dollars it held at the end of last year.
Management confirmed that the final analysis of the pivotal REGAL trial is expected this month. They also noted that a separate Phase 2 trial for their other drug candidate, SLS009, is fully enrolled with early data expected before the end of the year. For now, the company has enough cash to reach these key clinical milestones.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company will present data showing that its drug candidate SLS009, when used with other therapies, helped patients with high-risk acute myeloid leukemia (AML) who had failed previous treatments. Patients with specific genetic mutations saw response rates of 54 to 57 percent, and they lived significantly longer than the historical average for this patient group.
While the Phase 3 REGAL trial is the main focus for the company, these results suggest SLS009 could be a valuable second asset. It targets patients who currently have very few effective options, which could give the company another path to growth if the drug continues to perform well in larger studies.
Source: GlobeNewsWire
Management consistently hits its targets by a penny or two, showing they have a tight handle on the costs of their clinical trials. This steady record makes their spending forecasts reliable as they move toward filing for drug approvals.
| Expectation | |
|---|---|
| EPS | $-0.05 |
| Revenue | $36M |
Follow SELLAS Life Sciences to get the latest and most important updates.
Follow SLS